Sociedad Americana de Hirudoterapia

Chromosome-level Dinobdella ferox genome provided a molecular model for its specific parasitism

Genome assembly published in Parasites & Vectors (2023)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Genómica y proteómicaSeguridad y control de infeccionesGao JW et al. · Parasites & vectors, 2023

Abstract

BACKGROUND: Dinobdella ferox is the most frequently reported leech species parasitizing the mammalian nasal cavity. However, the molecular mechanism of this special parasitic behavior has remained largely unknown. METHODS: PacBio long-read sequencing, next-generation sequencing (NGS), and Hi-C sequencing were employed in this study to generate a novel genome of D. ferox, which was annotated with strong certainty using bioinformatics methods. The phylogenetic and genomic alterations of D. ferox were then studied extensively alongside the genomes of other closely related species. The obligatory parasitism mechanism of D. ferox was investigated using RNA-seq and proteomics data. RESULTS: PacBio long-read sequencing and NGS yielded an assembly of 228 Mb and contig N50 of 2.16 Mb. Along Hi-C sequencing, 96% of the sequences were anchored to nine linkage groups and a high-quality chromosome-level genome was generated. The completed genome included 19,242 protein-coding genes. For elucidating the molecular mechanism of nasal parasitism, transcriptome data were acquired from the digestive tract and front/rear ends of D. ferox. Examining secretory proteins in D. ferox saliva helped to identify intimate connections between these proteins and membrane proteins in nasal epithelial cells. These interacting proteins played important roles in extracellular matrix (ECM)-receptor interaction, tight junction, focal adhesion, and adherens junction. The interaction between D. ferox and mammalian nasal epithelial cells included three major steps of pattern recognition, mucin connection and breakdown, and repair of ECM. The remodeling of ECM between epithelial cells of the nasal mucosa and epithelial cells of D. ferox may produce a stable adhesion environment for parasitism. CONCLUSIONS: Our study represents the first-ever attempt to propose a molecular model for specific parasitism. This molecular model may serve as a practical reference for parasitism models of other species and a theoretical foundation for a molecular process of parasitism.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAnimalsPhylogenyModels, MolecularGenomicsHigh-Throughput Nucleotide SequencingNoseLeechesMammals

Resumen

Chromosome-level assembly of Dinobdella ferox (nasal-cavity-parasitizing leech) genome. Identifies expanded gene families relevant to specialized parasitism and immune evasion.

Por qué esto importa para la hirudoterapia

This study generated a chromosome-level genome assembly of Dinobdella ferox, a leech species that parasitizes the mammalian nasal cavity, using PacBio long-read sequencing, next-generation sequencing, and Hi-C, yielding a 228 Mb assembly with 19,242 protein-coding genes across nine linkage groups. RNA-seq and proteomics data from the digestive tract and body ends revealed that secretory proteins in D. ferox saliva interact with mammalian nasal epithelial cell membrane proteins involved in ECM-receptor interaction, tight junctions, focal adhesion, and adherens junction, defining a three-step parasitism model. This study is only tangentially relevant to ASH's domain: while it characterizes leech salivary secretory proteins, D. ferox is a nasal parasite rather than a species used in hirudotherapy, and the work addresses parasitism mechanisms rather than therapeutic bioactivity, anticoagulation, or clinical application.

Citación

Chromosome-level Dinobdella ferox genome provided a molecular model for its specific parasitism.

Gao JW et al. · Parasites & vectors, 2023

Contexto clínico relacionado

Explore cómo esta investigación se conecta con la práctica clínica

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.